Literature DB >> 1889233

Ki-67 and bromodeoxyuridine labeling of human choroidal melanoma cells.

D S Bardenstein1, D H Char, S Kaleta-Michaels, S M Kroll.   

Abstract

Understanding tumor growth patterns has implications for prognosis as well as for response and susceptibility to treatment. The antibody Ki-67 was used as a marker of cycling cells and bromodeoxyuridine (BrdUrd) was used as a marker of proliferating cells to characterize the cycling and proliferative rates of cells from human choroidal melanoma. The BrdUrd labeling indices varied from 0-1.1% and the Ki-67 labeling indices ranged from 0-3.0.3%. Linear regression modeling showed good correlation defined by the equation: Ki-67 index = 0.237 + 1.63 x BrdUrd labeling index with r = 0.919. Correlations between these indices and clinical and histologic parameters were not significant.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1889233     DOI: 10.3109/02713689109001755

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  4 in total

1.  Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas.

Authors:  C Chiquet; J D Grange; L Ayzac; P Chauvel; L M Patricot; M Devouassoux-Shisheboran
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region.

Authors:  M A Brantley; J W Harbour
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

3.  Association between gene expression profile, proliferation and metastasis in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; J William Harbour
Journal:  Curr Eye Res       Date:  2010-09       Impact factor: 2.424

4.  MIB-1 and PC-10 immunostaining for the assessment of proliferative activity in primary acquired melanosis without and with atypia.

Authors:  I Chowers; N Livni; A Solomon; G Zajicek; J Frucht-Pery; R Folberg; J Pe'er
Journal:  Br J Ophthalmol       Date:  1998-11       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.